Meeting
2019 ASCO Annual Meeting
Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.
Authors
Abby Statler
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Abby Statler , Annie Gupta , Cassann N. Blake , Wei (Auston) Wei , Brian P Hobbs , Zeina A. Nahleh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1032)
DOI
10.1200/JCO.2019.37.15_suppl.1032
Abstract #
1032
Poster Bd #
113
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
First Author: Marcela Carausu
Poster
2019 ASCO Quality Care Symposium
Visualizing treatment patterns and survival in metastatic breast cancer.
First Author: Aidan Gilbert
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese
Poster
2023 ASCO Annual Meeting
Breast cancer staging for patients with “low risk” disease: Are they all the same?
First Author: Jennifer Kay Plichta